Department of Psychiatry, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Via F. Sforza 35, 20122, Milan, Italy.
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Drugs R D. 2018 Mar;18(1):1-5. doi: 10.1007/s40268-017-0224-6.
Valproate is an effective anti-epileptic and mood stabilizer drug, but its prescription may be complicated by the development of thrombocytopenia. The purpose of the present manuscript is to provide a critical overview about the risk of thrombocytopenia during treatment with valproate. A search of the main database sources has been conducted to identify relevant papers about the topic. In the studies with a larger sample size (> 150 subjects), thrombocytopenia occurred in 12-18% of subjects receiving treatment with valproate. Advanced age, female gender, and high doses were found to be risk factors for the development of thrombocytopenia during treatment with valproate. Future research is needed to clarify the clinical impact of the occurrence of thrombocytopenia during valproate treatment (e.g., the risk of life-threatening events such as stroke or the development of thrombocytopenia during short- versus long-term administration, or oral versus intravenous formulations).
丙戊酸盐是一种有效的抗癫痫和情绪稳定剂药物，但由于其处方可能会导致血小板减少症的发生而变得复杂。本文的目的是对丙戊酸盐治疗期间发生血小板减少症的风险进行批判性综述。对主要数据库来源进行了搜索，以确定关于该主题的相关论文。在样本量较大（> 150 例）的研究中，接受丙戊酸盐治疗的患者中有 12-18%发生血小板减少症。高龄、女性和高剂量被发现是丙戊酸盐治疗期间发生血小板减少症的危险因素。需要进一步的研究来阐明丙戊酸盐治疗期间血小板减少症的发生对临床的影响（例如，发生危及生命的事件如中风的风险，或短期与长期给药期间或口服与静脉制剂期间血小板减少症的发生）。
